Clinical Study of Transcriptome-based Diagnostic Biomarker for Acute Febrile Illness

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Aug 11, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to quickly and accurately identify whether a person with a fever has a bacterial or viral infection. Currently, doctors rely on symptoms and traditional tests, which can lead to unnecessary use of antibiotics or delays in proper treatment. By examining specific markers from the body’s response to infection, this study aims to develop a faster and more reliable method to distinguish between the two types of infections. This could be especially helpful in areas with limited medical resources.

To participate in this trial, individuals need to have a fever of 38°C (100.4°F) or higher that has lasted less than 14 days. Participants must also be able to understand the study and give their consent. However, those with certain health conditions, such as cancer or autoimmune diseases, or who are pregnant, cannot take part. If you join the study, you can expect to undergo some tests that will help researchers understand how to improve diagnosis for future patients. This trial is currently looking for participants of all ages who meet the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. axillary temperature ≥38°C; 2. duration of fever shorter than 14 days; 3. subjects who are fully informed and agree to participate in this study.
• Exclusion Criteria:
• • 1.having comorbidities that may affect host gene expression, such as advanced malignancy, autoimmune diseases，immunodeficiency, or taking immune suppressors; 2.pregnancy; 3. mixed infection (viral combined with bacterial infection, autoimmune disease combined with bacterial infection); 4.incomplete clinical information; 5. For safety reasons or the interests of patients, clinicians believe that patients should not participate in any situation in this study.